MiniMed Group, Inc. MMED

MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that Sheila Denton has been named General Counsel & Corporate Secretary.

On September 1, 2026, MiniMed Group, Inc. (NASDAQ:MMED) reported first-quarter fiscal 2027 results for the period ended July 31, 2026. Worldwide net sales rose 16.6% as reported and 15.8% organically to $843 million, U.S. net sales grew 13.1%, and management raised full-year organic revenue growth guidance to approximately 10.5% from 10%. Bulls: Every New Product […]

MiniMed (Nasdaq: MMED) announced that it has filed a Form S-4 Registration Statement today with the Securities and Exchange Commission (the "SEC") in connection with Medtronic plc's ("Medtronic"; NYSE: MDT) offer to exchange up to 225,361,295 shares of MiniMed common stock, representing 80.1% of the total outstanding shares of MiniMed common stock, for outstanding Medtronic ordinary shares that are validly tendered and not validly withdrawn. If the exchange offer is oversubscribed, Medtronic int

Medtronic plc (Medtronic; NYSE: MDT) today announced that it has commenced an exchange offer to split off at least 80.1% of the shares of MiniMed Group, Inc. (MiniMed; Nasdaq: MMED). MiniMed, formerly Medtronic's Diabetes business, completed its initial public offering in March 2026 with Medtronic retaining an approximately 90% ownership interest in MiniMed. Through the exchange offer, Medtronic shareholders can exchange their Medtronic ordinary shares for shares of MiniMed common stock, subject

On September 1, MiniMed (NASDAQ:MMED) reported its first full quarter as a stand-alone public company, and the numbers suggest the split from Medtronic is already paying off. Revenue jumped 15.8% to $843 million, and management raised its full-year growth outlook just months after the IPO roadshow. The catalyst is simple. A new pump finally shipped, […]

MiniMed Group (NasdaqGS: MMED) reported a strong start to fiscal 2027, with management pointing to accelerated U.S. growth and broader international uptake. The company highlighted progress on next generation products, including trial completions that support its device pipeline. Regulatory updates included advancements with both FDA and CE Mark processes, alongside an improved revenue outlook for the fiscal year. For investors tracking how medical technology and software are reshaping...

MiniMed Group (NASDAQ:MMED) saw its share price increase by 10.66 percent on Tuesday to finish at $22.42 apiece after reporting strong revenues and earning a price target upgrade from an investment firm. In an earnings call on the same day, the company said that it was able to grow its revenues in the first quarter […]

Pfizer gained on vaccine and oncology growth, MiniMed on strong earnings, and Deere on AI-driven agriculture.

Minimed Group Inc (MMED) reports 15.8% organic revenue growth in Q1 2027, driven by successful product launches and robust international performance, while raising its full-year outlook.

Medtronic stock popped Tuesday as its diabetes spinoff MiniMed rallied after both lifted their full-year guidance.

Medtronic stock advances after the company posts better-than-expected quarterly earnings, raises revenue guidance, and announces a $700 million investment.